Evidence map›Paper›PMID 31615433›Full record

ArticleBMC infectious diseases2019

Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China.

Ni Wang, Hui Zhang, Yang Zhou, Hui Jiang, Bing Dai, Miaomiao Sun, Ying Li, Amelia Kinter, Fei Huang

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. eHealth in TB clinical management.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Pooled it
  3. Pooled it
  4. A randomised controlled trial to evaluate a medication monitoring system for TB treatment.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ni WangNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Hui ZhangNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Yang ZhouJiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, Jiangsu, China.
Hui JiangZhenjiang Center for Disease Prevention and Control, Zhenjiang, 212050, Jiangsu, China.
Bing DaiZhenjiang Center for Disease Prevention and Control, Zhenjiang, 212050, Jiangsu, China.
Miaomiao SunPATH China Program, Beijing, 100600, China.
Ying LiNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Amelia KinterPATH HIV and Tuberculosis Program, 455 Massachusetts Ave, Suite 1000, Washington, DC, 20001, USA.
Fei HuangNational Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. huangfei@chinacdc.cn.ORCID http://orcid.org/0000-0001-8620-3869
Chinese Center For Disease Control and Prevention · CNJiangsu Provincial Center for Disease Control and Prevention · CNProgram for Appropriate Technology in Health · US

Funding

Bill and Melinda Gates Foundation OPP1137180
6 · The paper itself

Abstract

backgroundIn settings such as China, where universal implementation of directly observed therapy (DOT) is not feasible, innovative approaches are needed to support patient adherence to TB treatment. The electronic medication monitor (EMM) is one of the digital technologies recommended by the World Health Organization (WHO), but evidence from implementation studies remains sparse. In this study, we evaluated acceptance of the EMM among health care workers and patients while implementing the device for differential TB patient management at the community level.

methodsZhenjiang City in Jiangsu Province was purposively selected for the study. All participating patients were allowed to select their preferred management approach. If patients declined to use the EMM, DOT was offered. The EMM was designed to hold 1 month of anti-TB drugs for once-daily dosing of fixed-dose combination (FDC) tablets. Patient EMM records were monitored monthly by a physician; if 20 to 50% of doses were missed twice, or more than 50% of doses were missed once, the patient was switched to DOT. The four physicians and five nurses involved in the study at four designated hospitals were surveyed using a structured questionnaire to assess their acceptance of the EMM.

resultsFrom October 2017 through January 2018, 316 pulmonary TB patients were notified in the TB information management system, and 231 (73.1%) met the study enrollment criteria. Although 186 patients (80.5%) initially consented to use the EMM, 17 later refused to use it. Among the 169 patients who used the EMM, 15 (8.9%) were switched to DOT due to poor adherence, and the other 154 completed the treatment course. The median adherence rate was 99.3%. Surveyed health care workers from designated hospitals found the EMM acceptable, although eight of nine felt use of the device moderately increased their workload. However, the EMM program significantly reduced the workload of community physicians by reducing patient visits by 87.9%.

conclusionsThis study demonstrated the acceptability of using an indigenously developed EMM for differential management of TB patients at the community level. However, more operational research should be conducted before introducing and scaling the technology throughout China.

Indexed as

AdolescentAdultAgedAged, 80 and overAntitubercular AgentsChildChinaDirectly Observed TherapyDrug MonitoringFemaleHumansMaleMedication AdherenceMiddle AgedTuberculosis, PulmonaryYoung AdultAntitubercular AgentsChinaElectronic medication monitorPatient managementTuberculosis

Identifiers

PMID31615433
PMCPMC6794727
OpenAlexW2981317584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.